PETER TRIPORO: Open Payments
NPI 1184050544 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,586 in 165 payments from 20 companies in 2025. Trend: 2023 $2,801 · 2024 $2,923 · 2025 $3,586
Food & beverage: $3,586
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 71 | $1,670 |
| Gilead Sciences, Inc. | 25 | $467 |
| Merck Sharp & Dohme LLC | 14 | $349 |
| EMD Serono, Inc. | 11 | $188 |
| ABBVIE INC. | 9 | $158 |
| Otsuka America Pharmaceutical, Inc. | 8 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $106 |
| Napo Pharmaceuticals Inc | 3 | $87 |
| PFIZER INC. | 4 | $86 |
| Theratechnologies Inc. | 3 | $82 |
Products named: CABENUVA, DOVATO, APRETUDE, PIFELTRO, REXULTI, RUKOBIA, VRAYLAR, CAPLYTA.
Industry payments across TX — which companies pay providers there.
